Beyond its use as a single agent in targeting YAP/TAZ-dependent cancers, we demonstrate that GNE-7883 suppresses the adaptive and intrinsic activation of YAP/TAZ target genes in the context of resistance to the KRAS G12C inhibitor sotorasib, and this combination was found to be highly efficacious and tolerated in a variety of xenograft models. The gene discussed is KRAS; the disease is cancer.